PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
Actinium Pharmaceuticals, Inc. (ATNM)
1.780.01 (-0.56%)
1.75 - 1.81
1.03 - 2.41
122.5K / 296.7K (Avg.)
-1.36 | -1.31
Identifies how quickly the company is scaling its balance sheet (via acquisitions, expansions, or debt). Strong growth, accompanied by sound fundamentals, can support long-term intrinsic value—while disproportionate debt expansion or bloated intangible assets can signal elevated risk.
-19.76%
Cash & equivalents declining -19.76% while TRVN's grows 32.46%. Howard Marks would question why our liquidity is shrinking while competitor builds cash.
No Data
No Data available this quarter, please select a different quarter.
-19.76%
Below half of TRVN's 3.10%. Michael Burry might suspect a liquidity shortfall if there's no alternative capital plan.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-58.43%
Other current assets growth 50-75% of TRVN's -100.00%. Bruce Berkowitz notes fewer expansions. Possibly simpler working capital.
-20.12%
Below half of TRVN's 6.07%. Michael Burry could suspect a liquidity squeeze. Verify operational performance.
13.37%
Below half TRVN's -4.39%. Michael Burry sees potential underinvestment risk unless there's a valid reason (asset-light model).
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
1.42%
Below half of TRVN's -3.19%. Michael Burry might suspect stagnation or lack of resources for expansions.
No Data
No Data available this quarter, please select a different quarter.
-19.74%
Below half of TRVN's 5.37%. Michael Burry sees a potential red flag for stagnation or capital shortage.
-6.57%
Less than half of TRVN's -57.32%. David Dodd sees a more disciplined AP approach or lower volume.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-100.00%
Less than half of TRVN's 3.17%. David Dodd sees fewer expansions in other current obligations.
-17.63%
Less than half of TRVN's 28.34%. David Dodd sees a more disciplined short-term liability approach.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-17.63%
Less than half of TRVN's 4.05%. David Dodd sees far fewer liability expansions relative to competitor.
0.13%
Less than half of TRVN's 8.82%. David Dodd sees fewer share issuances vs. competitor.
-2.90%
1.25-1.5x TRVN's -2.54%. Bruce Berkowitz notes stronger reinvestment strategy.
-5.63%
Less than half of TRVN's 56.52%. David Dodd sees fewer intangible or market-driven swings than competitor.
No Data
No Data available this quarter, please select a different quarter.
-20.37%
Below half TRVN's 6.55%. Michael Burry sees potential underperformance in building shareholder capital.
-19.74%
Below half TRVN's 5.37%. Michael Burry sees significant shrinkage or inactivity vs. competitor.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
19.76%
Less than half of TRVN's -109.28%. David Dodd sees better deleveraging or stronger cash buildup than competitor.